Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1

Status

Not yet recruiting 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 987Neoplasms 796Carcinoma, Non-Small-Cell Lung 763Prostatic Neoplasms 588Colorectal Neoplasms 484Lung Neoplasms 468Neoplasm Metastasis 413Multiple Myeloma 382Leukemia, Myeloid, Acute 377Ovarian Neoplasms 316Pancreatic Neoplasms 297Melanoma 278Squamous Cell Carcinoma of Head and Neck 258Recurrence 244Carcinoma, Hepatocellular 240Brain Neoplasms 226Glioblastoma 217Triple Negative Breast Neoplasms 204Carcinoma, Renal Cell 200Head and Neck Neoplasms 198Lymphoma 193Stomach Neoplasms 190Precursor Cell Lymphoblastic Leukemia-Lymphoma 189Sarcoma 172Glioma 171Uterine Cervical Neoplasms 169Lymphoma, Non-Hodgkin 169Endometrial Neoplasms 169Lymphoma, Large B-Cell, Diffuse 166Urinary Bladder Neoplasms 160

Interventions

Midazolam 2zanidatamab 1tislelizumab 1sitravatinib 1repaglinide 1pamiparib 1lenvatinib 1drospirenone 1Temozolomide 1HMPL-013 1Ethinyl Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × Advanced Malignancies × 90 days × Clear all
NCT04164199 2026-05-08

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Active not recruiting
404 enrolled

Advanced Malignancies

NCT07426757 2026-04-07

An Open-Label Study to Evaluate PF-07994525 in Participants With Advanced Cancers

Pfizer

Phase 1 Not yet recruiting
120 enrolled

Advanced Malignancies

NCT07340190 2026-04-02

A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

Novartis

Phase 1 Not yet recruiting
24 enrolled

Advanced Malignancies

NCT05351697 2026-03-17

BR105-I

BioRay Pharmaceutical Co., Ltd.

Phase 1 Terminated
31 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡